Luo HW - Search Results

1

Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.

Luo HW, Chen QB, Wan YP, Chen GX, Zhuo YJ, Cai ZD, Luo Z, Han ZD, Liang YX, Zhong WD. Luo HW, et al. Among authors: luo z. Biomed Pharmacother. 2016 Mar;78:116-120. doi: 10.1016/j.biopha.2016.01.004. Epub 2016 Jan 24. Biomed Pharmacother. 2016. PMID: 26898432

2

MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer.

Fu H, He HC, Han ZD, Wan YP, Luo HW, Huang YQ, Cai C, Liang YX, Dai QS, Jiang FN, Zhong WD. Fu H, et al. Among authors: luo hw. Tumour Biol. 2015 Mar;36(3):1983-91. doi: 10.1007/s13277-014-2805-0. Epub 2014 Nov 15. Tumour Biol. 2015. PMID: 25394900

3

Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer.

Zou J, Han Z, Zhou L, Cai C, Luo H, Huang Y, Liang Y, He H, Jiang F, Wang C, Zhong W. Zou J, et al. Med Oncol. 2015 Jan;32(1):373. doi: 10.1007/s12032-014-0373-1. Epub 2014 Dec 3. Med Oncol. 2015. PMID: 25465060

4

Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.

Wan Y, Zeng ZC, Xi M, Wan S, Hua W, Liu YL, Zhou YL, Luo HW, Jiang FN, Zhong WD. Wan Y, et al. Among authors: luo hw. Hum Pathol. 2015 Feb;46(2):295-303. doi: 10.1016/j.humpath.2014.10.027. Epub 2014 Nov 26. Hum Pathol. 2015. PMID: 25532941

5

Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.

Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD, Wu CL. Zhuo YJ, et al. Among authors: luo hw. Int J Mol Med. 2015 Apr;35(4):966-72. doi: 10.3892/ijmm.2015.2086. Epub 2015 Jan 30. Int J Mol Med. 2015. PMID: 25647485

6

Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.

Zeng YR, Han ZD, Wang C, Cai C, Huang YQ, Luo HW, Liu ZZ, Zhuo YJ, Dai QS, Zhao HB, Liang YX, Zhong WD. Zeng YR, et al. Among authors: luo hw. BMC Urol. 2015 Aug 29;15:90. doi: 10.1186/s12894-015-0085-7. BMC Urol. 2015. PMID: 26320076 Free PMC article.

7

[Association of BCL9 expression with prostate cancer clinicopathological features and survival].

He G, Yang S, Chen Y, Cai C, Zhuo Y, Luo H, Cai Z, Jiang F, Ling X. He G, et al. Zhonghua Yi Xue Za Zhi. 2015 Aug 25;95(32):2603-6. Zhonghua Yi Xue Za Zhi. 2015. PMID: 26711608 Chinese.

8

E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer.

Liang YX, Lu JM, Mo RJ, He HC, Xie J, Jiang FN, Lin ZY, Chen YR, Wu YD, Luo HW, Luo Z, Zhong WD. Liang YX, et al. Among authors: luo hw, luo z. Int J Oncol. 2016 Apr;48(4):1650-8. doi: 10.3892/ijo.2016.3364. Epub 2016 Jan 29. Int J Oncol. 2016. PMID: 26891801

9

BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression.

Ling XH, Chen ZY, Luo HW, Liu ZZ, Liang YK, Chen GX, Jiang FN, Zhong WD. Ling XH, et al. Among authors: luo hw. Oncol Lett. 2016 Mar;11(3):2001-2008. doi: 10.3892/ol.2016.4161. Epub 2016 Jan 29. Oncol Lett. 2016. PMID: 26998113 Free PMC article.

10

Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.

Wan YP, Xi M, He HC, Wan S, Hua W, Zen ZC, Liu YL, Zhou YL, Mo RJ, Zhuo YJ, Luo HW, Jiang FN, Zhong WD. Wan YP, et al. Among authors: luo hw. Oncol Res Treat. 2017;40(1-2):15-20. doi: 10.1159/000455145. Epub 2017 Jan 25. Oncol Res Treat. 2017. PMID: 28118628

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters